A significant communication gap exists between NMIBC patients and providers, with only 18% having regular discussions about ...
Zipalertinib's NDA submission is based on promising efficacy data from the REZILIENT1 trial, showing a 35.2% ORR and ...
Systemic immunotherapy is emerging as a bladder-sparing option for NMIBC, especially for patients unresponsive to BCG therapy ...
The FDA approved enfortumab vedotin and pembrolizumab for MIBC, following a priority review of their sBLA for neoadjuvant and ...
In this discussion, experts review findings from a large real-world dataset comparing clinical outcomes of 2 frontline ...
Dr. Hinrichs emphasizes the critical need for early referrals and screenings for patients considering advanced cell therapies, enhancing treatment outcomes.
Five-year follow-up data from the global, phase 2 JULIET (NCT02445248)trial, which evaluated the chimeric antigen receptor (CAR)T-cell therapy tisagenlecleucel (tisa-cel; Kymriah) in patients with ...
High LAG3 RNA expression in metastatic RCC is associated with improved ORR but not significant OS benefit, indicating adaptive immune resistance. Tumors with high LAG3 levels show robust infiltration ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback